Table 3 |
||||||
|
Multigene predictors of response to endocrine treatment |
||||||
|
Authors |
Signature |
Number of casesa |
Treatment |
Context |
Method |
Platform |
|
|
||||||
|
Jansen et al. [110] |
44 genes |
48 training set, 66 validation set |
TAM |
Recurrent breast cancer |
Top-down (response vs. progression) |
Microarray (local) |
|
Loi et al. [112] |
Tamoxifen predictor (181 genes) |
99 training set, 69 validation set 87 validation set |
TAM |
Adjuvant treatment |
Top-down (relapse vs. no relapse) |
Microarray (Affymetrix, Santa Clara, CA, USA) |
|
Oh et al. [111] |
Estrogen-regulated genes (822 genes) |
Cell lines + 65 discovery set, 60 validation set (1) |
Heterogeneous TAM (1) |
Adjuvant treatment |
Bottom-up (estrogen induced gene expression changes in MCF-7 cell lines) |
Microarray (Agilent Technologies, Inc., Santa Clara, CA, USA) |
|
90 validation set (2) |
TAM +/- NAC (2) |
|||||
|
250 validation set (3) |
Heterogeneous (3) |
|||||
|
Symmans et al. [113] |
SET index (165 genes) |
437 training set, 225 + 298 validation set (1) |
Heterogeneous TAM (1) |
Adjuvant treatment |
Bottom-up (genes coexpressed with estrogen receptor) |
Microarray (Affymetrix) |
|
122 validation set (2) |
NAC + TAM or Al (2) |
|||||
|
208 + 133 validation set (3) |
Non-treated (3) |
|||||
|
|
||||||
|
aNumber of cases in training and validation sets. AI, aromatase inhibitor; NAC, neoadjuvant chemotherapy; SET, sensitivity to endocrine therapy; TAM, tamoxifen. |
||||||
|
Colombo et al. Breast Cancer Research 2011 13:212 doi:10.1186/bcr2890 |
||||||